- Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors.
- The study has limitations due to its design.
- The findings reflect the changing nature of the pandemic.
Study: Pfizer COVID pill showed no benefit in younger adults
